Aridis Pharmaceuticals (NASDAQ:ARDS)‘s stock had its “buy” rating reissued by equities research analysts at Northland Securities in a report issued on Wednesday, April 17th, TipRanks reports. They presently have a $40.00 price target on the stock. Northland Securities’ price target suggests a potential upside of 334.78% from the stock’s previous close.
The analysts wrote, “We anticipate interim data from Aridis’ ongoing P3 trial in 1Q20, w/ TLR by YE20.””
Several other research analysts also recently issued reports on ARDS. Zacks Investment Research upgraded Aridis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research report on Tuesday, April 2nd. Maxim Group restated a “buy” rating and set a $25.00 price objective on shares of Aridis Pharmaceuticals in a research report on Monday, April 1st. ValuEngine downgraded Aridis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. Finally, Cantor Fitzgerald restated a “buy” rating and set a $25.00 price objective on shares of Aridis Pharmaceuticals in a research report on Wednesday, December 26th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $27.50.
Aridis Pharmaceuticals (NASDAQ:ARDS) last posted its quarterly earnings results on Thursday, March 28th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.55) by $0.88. The company had revenue of $1.39 million for the quarter, compared to analyst estimates of $0.30 million. On average, equities analysts predict that Aridis Pharmaceuticals will post -2.52 EPS for the current fiscal year.
Aridis Pharmaceuticals Company Profile
Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.
Further Reading: What is the price-sales ratio?
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.